The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Landscape of BRAF mutation classes in intrahepatic cholangiocarcinoma.
 
Tin-Yun Tang
Stock and Other Ownership Interests - Editas Medicine; Invitae; Uniqure
 
Anaemy Danner De Armas
No Relationships to Disclose
 
Jeffrey S. Ross
Employment - Foundation Medicine
Leadership - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine
Consulting or Advisory Role - Celsius Therapeutics; Tango Therapeutics
Research Funding - Foundation Medicine
 
Dean C. Pavlick
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
 
Radwa Sharaf
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
 
Benjamin G Kaplan
Employment - Foundation Medicine
Stock and Other Ownership Interests - Amarin Corporation (I); Individual investments each < $5,000 USD; Various investments owned by my parents, the specifics of which I am not privy too. (I)
Research Funding - Foundation Medicine
Patents, Royalties, Other Intellectual Property - Father holds ownership of Focus Reading Technologies and associated patents for enabling e-reading for a low-vision population. (I)
Other Relationship - Biotech Venture Fund (I)
(OPTIONAL) Uncompensated Relationships - In an informal, uncompensated role, my father advises Biotech Venture Fund (BVF) in exchange for the waiving of a management fee for investing with the hedge fund. (I)
 
Ethan Sokol
Employment - Foundation Medicine
Stock and Other Ownership Interests - Roche
Patents, Royalties, Other Intellectual Property - Submitted patent for HRD calling methodology (Inst)
 
Jordi Rodon Ahnert
Consulting or Advisory Role - Ellipses Pharma; iOnctura; Kelun Pharmaceuticals/Klus Pharma; Molecular Partners; Peptomyc
Research Funding - AADi (Inst); Amgen (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioAtla (Inst); BioMed Valley Discoveries (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Cellestia Biotech (Inst); Curis (Inst); CytomX Therapeutics (Inst); Deciphera (Inst); Fore Biotherapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Hummingbird (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); Kelun (Inst); Linnaeus Therapeutics (Inst); Loxo (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Nuvation Bio (Inst); Pfizer (Inst); Roche (Inst); Spectrum Pharmaceuticals (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst); Takeda/Millennium (Inst); Tango Therapeutics (Inst); Vall d'Hebron Institute of Oncology/Cancer Core Europe (Inst); Yingli Pharma (Inst)
Travel, Accommodations, Expenses - ESMO
Other Relationship - Boxer Capital; Chinese University of Hong Kong; Tang Advisors; Vall d'Hebron Institute of Oncology/Ministerio De Empleo Y Seguridad Social
 
Milind M. Javle
Honoraria - AstraZeneca/MedImmune; EMD Serono/Merck; Incyte; Merck; QED Therapeutics; TransThera Biosciences
Consulting or Advisory Role - AstraZeneca; Basilea Pharmaceutical; EMD Serono; incyte; Merck; Mundipharma; oncosil; QED Therapeutics
Other Relationship - Bayer; BeiGene; Incyte; Merck; Merck Serono; Novartis; Pieris Pharmaceuticals; QED Therapeutics; Rafael Pharmaceuticals; Seagen